This site is intended for healthcare professionals
Bladder cancer cells on a pink background
Accredited webinar: Bridging gaps in PTLD care

Accredited PTLD webinar: Session 3

​​Supported by Pierre Fabre​
Last updated: 7th Oct 2026
Published: 7th Oct 2026

Anticipating second‑line PTLD care: Evidence, access, and referral timing

How much do you know about evidence, access, and referral timing in the second-line management of PTLD?

Answer this question to find out. We’ll ask you the question again after you’ve watched the video to see what you recall.

1. A patient has persistent PTLD following first-line treatment. Which factor is most important when considering referral for additional treatment options?

Session 3. Sylvain Choquet (Pitié-Salpêtrière Hospital, Paris, France) reviews practical considerations for patients with relapsed or refractory PTLD, including treatment eligibility, referral pathways, specialist access, and emerging therapeutic approaches. The discussion also explores factors that may influence timely access to second-line treatment. View transcript.

This video is part of an accredited webinar video series for hematologists, transplant physicians, oncologists, and other healthcare professionals involved in the care of people with PTLD. Please note, this webinar is intended for healthcare professionals outside of the UK and Ireland only.

A total of 1 CME credit is available across all four episodes, with each episode worth up to 15 minutes of effective education time. To claim credit for an episode, complete the associated knowledge quiz and evaluation form after viewing the video. To claim credit for more than one video, complete the full assessment.

Important note: If you are not logged into your Medthority account, please complete the full session without exiting your browser. If you exit before finishing, you’ll need to restart from the beginning. We recommend logging in to preserve your progress if you need to pause. Not a member yet? You can set up your free account in just a few minutes.

Thank you for watching the webinar. Please answer these final questions to earn your CME credit.

1. A patient has persistent PTLD following first-line treatment. Which factor is most important when considering referral for additional treatment options?

2. The activity has been scientifically rigorous and evidence-based
3. I have identified bias
C. If yes, it has been

4. Please rate your level of agreement with the following statements (5 = Strongly agree; 1 = Strongly disagree):

Please complete the fields below to claim your CME credit.

Optional: I confirm that I am happy to receive further information about this video series and relevant Medthority updates by email.
Pierre Fabre Laboratoires

Developed by EPG Health for Medthority. This content has been developed independently of the sponsor, Pierre Fabre, which has had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.

This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 01:00 hours of effective education time.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the European Board for Accreditation of Continuing Education for Health Professionals, Royal College MOC Section 1 credits are deemed to be substantively equivalent to EBAC CPD credits.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA), the World Federation for Medical Education (WFME) CPD Recognition Committee, and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).